# Development and validation of a tool to stratify the treatment effect of low-dose aspirin in patients with cardiovascular disease: VISTA (Vascular Intervention Stratification Tool for Aspirin)

# Authors

Yekai Zhou BSc<sup>1</sup>\*, Joseph Edgar Blais BScPharm, PhD<sup>2</sup>\*, Esther Wai Yin Chan BPharm(Hons), PhD<sup>2,3</sup>, Tak-Wah Lam PhD<sup>1</sup>, Kai Hang Yiu MD, PhD<sup>4</sup>, Hung Fat Tse MD, PhD<sup>4</sup>, Celine SL Chui PhD<sup>3,5,6#</sup>, Ruibang Luo PhD<sup>1#</sup>

#### \*Co-first authors #Corresponding authors

<sup>1</sup> Department of Computer Science, The University of Hong Kong, Hong Kong Special Administration Region, China

 <sup>2</sup> Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region, China
 <sup>3</sup> Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China
 <sup>4</sup> Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administration Region, China

<sup>5</sup> School of Nursing, The University of Hong Kong, 5/F Academic Building, 3 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, China

<sup>6</sup> School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China

Short Title: Predicting low-dose aspirin treatment effect

### **Corresponding Authors**

Prof Celine Sze Ling Chui, 5/F Academic Building, 3 Sassoon Road, Pokfulam, Hong Kong Special Administration Region, China. Email: <u>cslchui@hku.hk</u>

Prof Ruibang Luo, Rm 301 Chow Yei Ching Building, The University of Hong Kong, Pokfulam Road, Pokfulam, Hong Kong Special Administration Region, China. Email: <u>rbluo@cs.hku.hk</u>

### Manuscript word count: 3911

#### Abstract

#### Background

Aspirin resistance, as determined by measuring platelet aggregation function, has been investigated as a proxy outcome for clinical treatment failure with low-dose aspirin (occurrence of cardiovascular events despite regular aspirin intake). However, among adults with cardiovascular disease (CVD), there is no method to predict aspirin treatment failure using routinely available clinical data. We aimed to develop and internally validate the Vascular Intervention Stratification Tool for Aspirin (VISTA), a model that predicts inter-individual variability in clinical response to low-dose aspirin.

#### Methods

We used electronic health records of the Hong Kong Hospital Authority to identify derivation (n=48,743) and validation (n=322,731) cohorts consisting of individuals diagnosed with CVD between January 1, 2015 to December 31, 2018. The composite outcome of recurrent CVD event included the diagnosis of coronary heart disease, ischemic stroke, and peripheral artery disease after low-dose aspirin initiation ( $\leq$  100 mg). Cox proportional hazards regression with the least absolute shrinkage and selection operator regularization was used to identify the most strongly associated and relevant risk factors for aspirin treatment failure. One-year hazard ratio (HR) was estimated across different risk categories for aspirin treated vs. untreated individuals.

#### Results

The derivation cohort included 1,623 individuals who initiated low-dose aspirin after their CVD diagnosis. Among 109 variables available, six were selected as model inputs: atrial fibrillation, dyslipidemia, hyperglycemia, polypharmacy, neutrophilia, and elevated serum creatine kinase. In the model validation cohort, we identified 22,192 individuals who initiated low-dose aspirin and 3,747 individuals without aspirin, other antiplatelets, or anticoagulants. Results of the model validation demonstrated a strong graded association between the number of VISTA risk factors and the one-year risk of CVD. Compared to untreated individuals, low-dose aspirin use with no VISTA risk factors had the lowest HR for CVD (0.68, 95% CI of 0.57 to 0.81). For low-dose aspirin user with 1-2 VISTA risk factors, HRs was 0.87 (0.81 to 0.93). The presence of 3-6 VISTA risk factors was associated with aspirin treatment failure (HR 0.99; 95% CI of 0.88 to 1.12), which occurred in approximately 20% of patients in our validation cohort.

#### Conclusions

VISTA can predict the heterogeneity of low-dose aspirin's treatment effect against recurrent CVD. VISTA could be used to stratify patients based on six readily available risk factors and inform patients and clinicians about the potential benefits of aspirin therapy and the potential for alternate antiplatelet treatments.

**Keywords:** Low-dose aspirin, aspirin treatment failure, aspirin resistance, stratified medicine, heterogeneity of treatment effect, secondary prevention, risk prediction model, electronic health records

# **Clinical perspective**

#### What is new?

• We developed VISTA (Vascular Intervention Stratification Tool for Aspirin), the first tool that enables the stratification of low-dose aspirin treatment effect for the secondary prevention of cardiovascular disease (CVD). By utilizing six easily accessible clinical risk factors (atrial fibrillation, dyslipidemia, hyperglycemia, polypharmacy, neutrophilia, and elevated serum creatine kinase), VISTA allows for the assessment of aspirin suitability before prescription.

• VISTA can differentiate patients who are likely to benefit significantly from aspirin treatment (0 risk factors, hazard ratio [HR] of 0.68) from those who may experience aspirin treatment failure (3-6 risk factors, HR of 0.99).

### What are the clinical implications?

• Estimated from a high-quality contemporary validation cohort, there are approximately 20% of patients with CVD who may experience aspirin treatment failure.

• By utilizing VISTA, healthcare providers can personalize aspirin treatment, optimizing its effectiveness and minimizing the potential for treatment failure. This tool empowers clinicians to make more accurate and tailored decisions in prescribing low-dose aspirin for secondary prevention of cardiovascular disease, ultimately leading to improved patient outcomes.

#### 1 Introduction

2

Cardiovascular diseases (CVD), such as coronary heart disease and stroke, are the leading 3

- cause of death worldwide, resulting in an estimated 18.6 million fatalities in 2019.<sup>1,2</sup> Aspirin, 4
- or acetylsalicylic acid, has long been recognized as a crucial intervention to improve CVD 5
- outcomes due to its antiplatelet properties, particularly in secondary prevention of CVD.<sup>3,4</sup> 6
- 7 However, the occurrence of occlusive CVD events despite regular aspirin intake, a
- phenomenon known as aspirin treatment failure, poses a significant clinical challenge.<sup>5-10</sup> 8
- 9 Identifying patients who may have limited benefit from CVD prevention with aspirin but are
- 10 exposed to an elevated risk of major organ bleeding is essential for appropriate aspirin
- 11 prescription and selection of suitable antiplatelet treatments for CVD prevention.<sup>11</sup>
- 12 Although methods exist to indirectly query aspirin effectiveness via platelet aggregation
- 13 function tests, there are currently no solutions available to predict aspirin treatment failure in clinical settings.<sup>5,12-15</sup>
- 14
- 15

Existing methods for evaluating aspirin effectiveness involve assays that test a laboratory 16

- phenomenon called aspirin resistance.<sup>5</sup> These assays, including the platelet function 17
- analyzer (PFA-100), whole blood aggregometry (WBA), and VerifyNow aspirin assay 18
- 19 (VerifyNow), quantify and compare the platelet aggregation function before and after the
- administration of aspirin.<sup>5,12-15</sup> However, these assays have limitations when it comes to 20
- 21 aspirin prescriptions. First, they serve only as risk indicators, similar to age and lipid levels;
- they cannot measure the treatment effect of aspirin.<sup>16,17</sup> Second, these assays utilize 22
- 23 different techniques, resulting in poor agreement even among the same group of
- 24 patients.<sup>18-25</sup> This lack of consistency adds to the difficulty for clinicians in selecting the most
- 25 appropriate assay. Third, these assays are not endorsed by clinical guidelines and are not
- 26 typically available in general hospital settings, limiting their use as routine tests for aspirin
- prescription reference.<sup>26,27</sup> Therefore, there is an urgent need for a method based on easily 27
- 28 accessible patient characteristics that can directly estimate the treatment effect of aspirin in 29 CVD prevention.
- 30
- 31 In this study, we present the development and validation of the Vascular Intervention 32 Stratification Tool for Aspirin (VISTA), which was designed to stratify the treatment effect of
- 33 aspirin for the prevention of recurrent CVD events. VISTA is based on six easily accessible
- 34 patient characteristics that can be assessed prior to aspirin prescription in actual clinical
- 35 settings. We conducted a large, comprehensive cohort study in Hong Kong, encompassing a
- 36 wide range of potential risk factors. By employing advanced big data approaches, we
- 37 analyzed this extensive dataset to identify the most significant risk factors contributing to 38 the variation in aspirin treatment effects. The validity of the identified risk factors was then
- 39 confirmed in a separate validation cohort, which demonstrated their accuracy in stratifying
- 40 the treatment effects of aspirin. Our method provides a straightforward estimation of
- 41 aspirin's treatment effect, serving as a tool to assess its potential benefits for individual
- 42 patients. Leveraging VISTA's capabilities, clinicians gain early access to this information,
- 43 enabling informed decisions about aspirin therapy suitability.
- 44
- 45 Methods
- 46 Data source

47 Two contemporary cohorts were identified for model derivation and validation from the

- 48 electronic health records of the Hong Kong Hospital Authority (HA) with rigorous inclusion
- 49 criteria (Figure 1). The HA is a statutory body and the largest public healthcare provider of
- 50 Hong Kong. It provides government subsidized primary, secondary, and tertiary care for all
- 51 residents who want it, capturing over 70% of all hospitalizations in Hong Kong.<sup>28</sup> Previous 52 studies demonstrated the high validity of the data source, with a positive predictive value of
- studies demonstrated the high validity of the data source, with a positive predictive value
   85% for myocardial infarction (MI) and 91% for stroke.<sup>29</sup> Because patients are provided
- 54 outpatient medications at very low out-of-pocket cost, dispensing records for low-dose
- 55 aspirin are recorded in the HA database. This makes it suitable to investigate the chronic
- 56 effects of low-dose aspirin, which may not be feasible in many other health systems where
- 57 patients purchase aspirin as an over-the-counter medication without prescription or
- 58 recording.<sup>30</sup>
- 59

## 60 Study cohorts and eligibility criteria

61 We included patients who 1) had their first CVD diagnosis recorded between 1 January 2015

and 31 December 2018, 2) did not have an aspirin prescription dispensed before the index CVD event, and 3) had a prescription record for low-dose ( $\leq$  100mg) aspirin daily until the

- $c_{1}$  and of study follow we as did not have any prescription record for period aspirit daily until the
- end of study follow-up, or did not have any prescription record for aspirin at any dose until
   the end point of their study (as the control group to compare with the treated patients to
- 65 the end point of their study (as the control group to compare with the treated patients to 66 calculate the treatment effect of aspirin).The cohort entry date was the date of their first
- 67 diagnosis of CVD in any inpatient or outpatient setting. Patients were followed until the
- 68 earliest occurrence of the composite recurrent CVD outcome, date of registered death, one
- 69 year after their index CVD diagnosis, or the study end date (31 December 2019). We did not
- 70 include patients with CVD diagnosis within one year before the study end date to ensure the
- 71 patients would have sufficient exposure to aspirin therapy. Daily aspirin users whose most
- 72 frequently visited healthcare facility within the study period was on Hong Kong Island were
- categorized as the Hong Kong Island cohort for model derivation. Patients with their most
- 74 frequently visited healthcare facility within the study period was on Kowloon and New
- 75 Territories were categorized as the Kowloon and New Territories cohort for model
- validation. The daily aspirin users were in the treatment group and the non-aspirin users in
- 77 the untreated (control) group.
- 78

# 79 Exposure, outcomes and risk factor variables

80 The included patients had a CVD diagnosis (coronary heart disease, ischemic stroke, and

- 81 peripheral artery disease) between January 1, 2015, and December 31, 2018. Patients were
- 82 not prescribed low-dose (≤ 100 mg) aspirin before the CVD event. The control group
- 83 patients were not treated with low-dose aspirin before their censored date. The control
- 84 group patients received sufficient daily low-dose aspirin treatment from the date of CVD
- 85 event to their censored date.
- 86
- 87 The outcome was the diagnosis of CVD defined by the International Classification of
- 88 Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. The outcome was a
- 89 composite of coronary heart disease, ischaemic or haemorrhagic stroke, and peripheral
- 90 artery disease (Supplementary Table 1).
- 91
- 92 We compiled an extensive list of over 100 variables to ensure the selection of
- 93 representative risk factors. The list encompassed clinical laboratory tests, disease and

94 medication history, family history of disease, demographic factors, and healthcare utilization 95 (Table 2). Diagnoses and procedures were defined by ICD-9-CM codes (Supplementary Table 96 2), and medication history was defined by the British National Formulary (BNF) sections

- 97 (Supplementary Table 3).
- 98

#### 99 Statistical analysis

100 A robust feature selection pipeline was applied to identify the risk variables for model derivation.<sup>31,32</sup> Multivariate imputation with chained equations (MICE) was used to generate 101 one imputed dataset to replace the missing values of clinical laboratory tests.<sup>33</sup> MICE is a 102 103 principled method for dealing with missing data and is extremely reliable on highdimensional datasets with various missing patterns.<sup>34</sup> For better statistical reliability and 104 105 clinical utility, risk variables with missing rates below 20% (e.g., clinical laboratory tests) and an event rate above 1% (e.g., disease and medication history) were passed for feature 106 107 selection. We employed a Cox proportional hazards model (CPH) with the least absolute 108 shrinkage and selection operator (LASSO) regularization to shortlist statistically significant (p value<0.05) risk variables.<sup>35,36</sup> CPH is the most widely used multivariate statistical model for 109 survival analysis.<sup>37,38</sup> Its regression coefficients can be interpreted as hazard ratios which can 110 be easily understood by clinicians for better decision-making. LASSO is a robust feature 111 112 selection method. It selects the most representative but independent set of risk variables, 113 which is reliable when downstream manual prioritization is required. The final list of risk 114 variables was also determined based on current clinical evidence to ensure the final set of 115 risk variables are comprehensive and relevant to CVD prognosis. The identified continuous 116 risk variables were converted to categorical form based on clinical diagnosis criteria. Each 117 risk variable was weighted as one point, and the risk category was defined as the total 118 number of risk factors for each patient.

119

120 Patients in the validation cohort were assigned risk categories based on the identified risk

121 variables. One-year CVD risk was calculated for patients within different risk categories in

the treatment and control groups respectively using the Kaplan-Meier method.<sup>39</sup> The 122

123 treatment effect and the confidence interval across different risk categories were calculated

124 as the coefficient in CPH, which was trained on the composite of treatment and control

125 group patients with treatment as a covariate in each risk category. All analyses were

conducted using Python (version 3.9.1), with its add-on package lifelines.<sup>40</sup> This study report 126 is in accordance with the TRIPOD statement.<sup>41</sup> Ethical approval for this study was granted by 127

the Institutional Review Board of The University of Hong Kong/HA Hong Kong West Cluster 128 (UW24-124).

129

# 130

#### 131 Results

132 Study cohorts

133 For the derivation cohort, we initially identified 48,743 patients aged 18 or above with lipid 134 test records and diagnosis of CVD at hospitals in the Hong Kong West Cluster. We excluded

135 39,262 patients whose first CVD event occurred before January 1, 2015, or after December

- 136 31, 2018. We excluded 3,169 patients with low dose aspirin treatment before their first CVD.
- 137 We excluded 4,546 patients with no daily aspirin treatment after CVD. We excluded 140
- 138 patients with anticoagulant or other antiplatelet treatments before or after CVD. We
- 139 excluded 3 patients with the first CVD diagnosis of hemorrhagic stroke. Overall, 1,623

patients (selected out of 48,743 patients) who took aspirin daily were included in the HongKong Island cohort for model derivation.

142

143 For the validation cohort, we initially identified a cohort of 322,731 patients aged 35 or

- above with blood pressure records and diagnosis of CVD by the Hospital Authority. Similar
- 145 exclusion criteria were applied to the validation cohort. A total of 245,188 patients were
- 146 excluded who had their first CVD event before January 1, 2015 or after December 31, 2018.
- 147 A total of 28,902 of patients were excluded who had low dose aspirin treatment before their
- 148 first CVD. A total of 8,372 patients were excluded who had received aspirin treatment after
- 149 CVD, but not daily. A total of 580 patients were excluded because of immediate CVD death.
- 150 To ensure no overlap with the derivation cohort, we excluded 6,845 patients with most
- 151 frequently visited healthcare utilization on the Hong Kong Island. We excluded 1,619
- 152 patients with anticoagulant or other antiplatelet treatments before or after CVD. We
- excluded 5,286 patients with the first CVD diagnosis of hemorrhagic stroke. Overall, 25,939
- 154 patients (selected out of 322,731 patients) were included in the Kowloon and New
- 155 Territories cohort for model validation; 22,192 daily aspirin users were assigned to the
- 156 treatment group and 3,747 non aspirin users were assigned to the control group.
- 157
- 158 Baseline characteristics
- 159 The baseline characteristics were similar across the cohorts and subgroups, to ensure the
- 160 reliability of our selection criteria and support the subsequent model derivation and
- 161 validation (Table 1). The median age at the cohort entry date was 67 to 75, and 35–48% of
- 162 the patients were female. A considerable proportion of the patients had comorbidities: 12-
- 163 23% with dyslipidemia, 30-40% with hypertension, 19-20% with diabetes, 3-10% with atrial
- 164 fibrillation, 3-5% with chronic kidney disease, and 6-7% with congestive heart failure.
- 165 Regarding medication history, 18-21% of patients had received statin therapy, 15-22% of
- 166 patients had taken antidiabetic drugs, and 42-65% of patients were on antihypertensive
- 167 drugs. The median number of concurrent medications was 6-7.
- 168
- 169 *Model development*
- 170 The complete list of all available variables and the details of the feature selection process
- 171 are shown in Table 2. There were initially 109 risk variables under consideration. We
- excluded 38 of them with a high missing rate (>20%) or low event rate (<1%) from
- 173 subsequent LASSO regression for better statistical reliability and clinical utility. The LASSO
- regression on the remaining variables identified 7 statistically significant (p value < 0.05)
- variables. We shortlisted 4 of them based on clinical evidence. We replaced the use of
- antiplatelet drugs with fasting glucose level as a measure of diabetic inclination due to the
- 177 higher data completeness of the latter. We added atrial fibrillation to the final list
- 178 considering its established role in suboptimal aspirin effectiveness.<sup>42,43</sup> We translated the
- selected numerical variables, namely neutrophil count, creatine kinase, glucose levels, and
- 180 concurrent medication, into categorical variables based on specific diagnostic criteria.
- 181 Neutrophil count was categorized as neutrophilia (neutrophil count > 7.5 \* 10^9/L), creatine
- 182 kinase was categorized as elevated CK (defined as CK > 400 IU/L), glucose levels were
- 183 categorized as hyperglycemia (glucose > 7 mmol/L), and concurrent medication was
- 184 categorized as polypharmacy (concurrent medication > 4).
- 185

The identified risk factors encompassed a comprehensive spectrum of direct and indirect 186 187 causes that contributed aspirin suboptimal effects, which were supported by the literature. 188 First, while aspirin is more effective in atherosclerotic CVD, its effectiveness in other types of CVD may be limited.<sup>44</sup> Aspirin has limited efficacy for stroke prevention in patients with 189 atrial fibrillation.<sup>43</sup> Neutrophilia may serve as an indicator of inflammation signaling arteritis 190 which compromise the efficacy of aspirin.<sup>44,45</sup> Elevated CK, an indicator of muscle damage, is 191 192 a possible sign of cardiomyopathy or myonecrosis, which could potentially impact the response to aspirin treatment.<sup>46,47</sup> Specific comorbidities and prevalent drug use may also 193 194 affect the treatment effect of aspirin. Polypharmacy can lead to drug interactions that 195 interfere with the effect of aspirin. Hyperglycemia and dyslipidemia may hinder the 196 intended antiplatelet effects of aspirin by increasing the production of prostaglandin F2-like compounds.<sup>48-50</sup> The final list of the 6 risk factors was then utilized in the CPH. The 197 198 parameter estimates for each of the 6 predictor variables showed statistical significance and 199 were of similar magnitude (Table 3).

200

201 To facilitate practical implementation, we adopted a pragmatic approach by categorizing the

202 suboptimal aspirin treatment effect based on the number of risk factors present in an

203 individual. This risk stratification strategy allows for a straightforward assessment of the

204 likelihood and extent of suboptimal aspirin response based on the number and nature of

- 205 identified risk factors.
- 206

# 207 Model validation

We compared the outcomes in the treatment and control group across different risk categories with different number of risk factors in the validation cohort (Figure 2). For the

ease of clinical use and model stability, we defined 3 risk categories regarding the total

number of 0, 1-2, and 3-6 risk factors (out of 6) for aspirin treatment effect stratification.

Around 80% of patients (79.7% in the treatment group and 78.7% in the control group) were

- in the risk categories with less than three risk factors. The results showed that patients had
- similar baseline one-year CVD recurrence risk regardless of the risk category (from 43.5%
- with 0 risk factors to 52.4% with 3-6 risk factors in the control group). In contrast, the
- 216 recurrence risk with aspirin treatment showed strong graded association with the risk
- 217 categories (from 34.0% with 0 risk factors to 54.5% with -6 risk factors in the aspirin
- 218 treatment group). The stable baseline risk and the graded risk after treatment showed the
- 219 robustness of the risk factors that we identified. As the number of risk factors increased,
- 220 there was a gradual approaching tendency in the CVD risk between the treatment and
- 221 control group. This indicated that aspirin treatment might be more effective in individuals
- 222 with fewer risk factors than those with multiple risk factors.
- 223

224 The HR of aspirin treatment, estimated based on both groups, exhibited a similar trend 225 (Table 4). Specifically, patients with no risk factors (14.2% of patients) had an aspirin 226 treatment HR of 0.68. This suggested that aspirin treatment significantly reduced the risk of 227 CVD events in this low-risk subgroup. For patients with 1-2 risk factors, which constituted 228 64.8% of the cohort, the aspirin treatment HR is 0.87. Although the effect size was slightly 229 attenuated compared to the no-risk factor group, these individuals still benefited from 230 aspirin treatment as indicated by the reduced HR. In contrast, the remaining 21.0% of 231 patients with 3-6 risk factors exhibited an aspirin treatment HR of 0.99. This group of high-

- risk patients may be referred to as had aspirin treatment failure, since aspirin therapy did
- 233 not provide an additional protective effect against CVD events.
- 234
- 235 Website design

236 A website employed VISTA at www.bio8.cs.hku.hk/vista.html (Supplementary Information 1)

- 237 was deployed for demonstration, and to enhance utility and clinician-patient discussions.
- 238

# Discussion

240 Our study represents the first investigation, to the best of our knowledge, into the impact of 241 patient characteristics on the effectiveness of low-dose aspirin for preventing recurrent CVD 242 events in secondary prevention. We conducted rigorous statistical testing on a large pool of 243 variables and identified six relevant risk factors, which encompass potential mechanisms 244 underlying suboptimal treatment effects of aspirin. The results of our model validation 245 further demonstrated the strong performance of our model in stratifying aspirin treatment 246 effects. By leveraging VISTA's capabilities, clinicians gain early access to the potential 247 benefits of aspirin therapy as a treatment option for each patient, allowing them to make 248 informed decisions regarding its suitability. The tool enables clinicians to assess a patient's 249 risk of treatment failure and proactively adjust the medication regimen by considering 250 alternative therapeutic approaches. For instance, if a patient exhibits a high risk of 251 treatment failure, the clinician can opt to rely on other medications, such as setting lower 252 targets for blood pressure and LDL cholesterol with a higher intensity of antihypertensive 253 and lipid-lowering agents. By optimizing the combination of medications based on individual 254 patient characteristics, this decision support tool has the potential to enhance treatment 255 efficacy and improve outcomes in the secondary prevention of CVD.

256

257 Optimizing the prescription of low-dose aspirin for CVD prevention requires a

258 comprehensive evaluation of both the potential bleeding risk and the treatment effect. 259 While a study has attempted on this objective, it only predicted the bleeding risk, without assessing the treatment benefit.<sup>51</sup> In scenarios where the predicted treatment benefit is 260 unknown, clinicians may only rely on the bleeding risk as a reference. If the bleeding risk is 261 not high, aspirin may be considered as a viable option, even though the benefit remains 262 263 uncertain. Conversely, if the estimated benefit from aspirin is modest, regardless of how low 264 the bleeding risk is, it is advisable to avoid prescribing aspirin and instead prioritize other 265 medications to achieve the targeted treatment objective. Our study addresses this limitation 266 by directly assessing the treatment effect of aspirin, offering a more comprehensive 267 perspective. Moreover, the bleeding risk study identified 20 risk factors that were 268 associated with the bleeding risk. However, only one of them overlapped with our identified 269 risk factors (diabetes), while the other 19 of them were not associated with treatment 270 failure. This disparity suggests that the treatment benefit and bleeding risk operate through 271 distinct mechanisms and systems. It emphasizes the significance of our study in prompting 272 clinicians to consider the benefit-risk scenario differently when prescribing aspirin.

273

Aspirin treatment failure has long been recognized as important consideration in clinical

- 275 practice. Existing methods for assessing aspirin's antiplatelet effects rely on specific
- 276 laboratory tests, such as PFA-100, WBA, and VerifyNow, which measure individual platelet
- function to predict the effectiveness of aspirin. Several case studies have shown that aspirin
- resistance, as indicated by these assays, is associated with a higher rate of CVD events.<sup>16,52</sup>

279 However, these tests are not readily available in general hospital settings and have modest 280 correlation and agreement. For instance, in a study of 201 patients with stable coronary 281 artery disease receiving >80mg/day of aspirin, the prevalence of aspirin resistance varied greatly: 7% from VerifyNow, 18% from WBA, and 60% from PFA-100.<sup>18</sup> Also, they do not 282 283 directly predict the effectiveness of aspirin in preventing CVD, limiting their practical 284 usefulness for clinicians' reference. In contrast, our study proposes a practical method that 285 utilizes easily accessible variables to predict the treatment effect of aspirin on CVD 286 prevention. According to the validation results, approximately 80% of patients are expected 287 to experience a considerable treatment effect from aspirin, with hazard ratios ranging from 288 0.67 to 0.83. However, approximately 20% of patients may have treatment failure (HR close 289 to 1.00) from aspirin if two or more risk factors are present. The findings from our research 290 provide valuable guidance for clinicians in the decision-making process of prescribing aspirin. 291 By offering a straightforward estimation of aspirin's treatment effect, our method can be 292 used as a tool to assess the potential benefits of aspirin as a treatment option for each 293 patient.

294

295 Our work introduced a novel lens to investigate treatment recommendation methods in the 296 era of big data. Traditional approaches to evaluate treatment effects rely on randomized 297 controlled trials (RCTs). RCTs face practical constraints, cost considerations, and data 298 management complexities, which often lead to the collection of a limited number of patient 299 characteristics. While RCTs are reliable in yielding population-level outcomes, stratifying 300 individual benefits based on these limited covariates is challenging. In our research, we 301 demonstrated the potential of high-quality retrospective cohort studies with a 302 comprehensive set of covariates in treatment effect stratification. We utilized a robust 303 feature selection process to identify key risk factors in aspirin efficacy variation and applied 304 rigorous validation to estimate the variation of the treatment effects across various risk 305 groups. In the era of big data and with advances in data curation, there is an opportunity to 306 develop more robust treatment effect stratification that complements the population-level 307 results obtained from RCTs. Our approach has proved to be robust in addressing this task 308 and can be extended to analyze the efficacy of various therapies. By leveraging the vast 309 amount of available data, we can gain valuable insights into individual treatment responses 310 and enhance personalized medicine approaches. 311

312 There are limitations in our study. First, both our derivation and validation cohorts were 313 developed using data from Hong Kong. Although Hong Kong is a multi-ethnic city, its 314 population is predominantly Chinese. Consequently, the generalizability of our model's 315 performance to other ethnicities and regions may be uncertain. Future research should aim 316 to apply our model to validation cohorts comprising diverse ethnic populations to assess its 317 performance across different racial groups. Second, our estimation of treatment effects 318 across risk groups was based on a retrospective cohort study design. This introduces the 319 possibility of selection bias in the selection of the treatment and control groups. To further 320 validate our model, it would be beneficial to conduct more rigorous investigations, such as 321 prospective clinical studies that incorporate the collection of the identified key risk factors. 322 This independent validation of each risk factor and evaluation of the performance of risk 323 group treatment stratification would provide stronger evidence for the effectiveness and 324 reliability of our model.

325

### 326 Conclusions

327 The variability in aspirin treatment effects poses a significant challenge in optimizing

328 therapeutic outcomes for patients with CVD. VISTA can be helpful in the secondary

329 prevention of CVD which can identify patients who may be at risk of treatment failure thus

- help clinicians with treatment planning. We identified six key risk factors, history of atrial
- 331 fibrillation, dyslipidemia, hyperglycemia, polypharmacy, neutrophilia, and elevated CK, that
- contribute to the variation in aspirin treatment effects. The big-data approach employed in
- 333 our study also holds promise across various therapeutic areas beyond aspirin therapy. This 334 research represents a significant step towards advancing personalized medicine in aspirin
- research represents a significant step towards advancing personalized medicine in aspirin therapy, ultimately enhancing therapeutic effectiveness and improving CVD prevention on
- 336 an individualized basis.
- 337

# 338 Acknowledgements

339 Nil.

340

# 341 Sources of funding

342 Nil.

# 343

# 344 Disclosures

EWYC reports honorarium from Hospital Authority; and grants from Research Grants Council
(RGC, Hong Kong), Research Fund Secretariat of the Food and Health Bureau, National
Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen,
Amgen, Takeda, and Narcotics Division of the Security Bureau of the Hong Kong Special
Administrative Region, outside the submitted work. CSLC has received grants from the Food
and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong

- 351 Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD, and Amgen; and personal
- 352 fees from PrimeVigilance; outside the submitted work. RL has received grants from Hong
- 353 Kong Research Grant Council, Hong Kong Innovation and Technology Commission; and

354 research donations from Oxford Nanopore Technologies, outside the submitted work. All

- 355 other authors declare no competing interests.
- 356

# 357 References

Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases
 and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol* 2020;
 **76**(25): 2982-3021.

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and
 injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global
 Burden of Disease Study 2019. *Lancet* 2020; **396**(10258): 1204-22.

- 364 3. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of 365 death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various 366 categories of patients. Antiplatelet Trialists' Collaboration. *BMJ* 1994; **308**(6921): 81-106.
- 367 4. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of
- antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk
  patients. *BMJ* 2002; **324**(7329): 71-86.

3705.Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat371Rev Drug Discov 2003; 2(1): 15-28.

372 6. Neergaard-Petersen S, Ajjan R, Hvas AM, et al. Fibrin clot structure and platelet 373 aggregation in patients with aspirin treatment failure. PLoS One 2013; 8(8): e71150. 374 Chu JW, Wong CK, Chambers J, Wout JV, Herbison P, Tang EW. Aspirin resistance 7. 375 determined from a bed-side test in patients suspected to have acute coronary syndrome 376 portends a worse 6 months outcome. QJM 2010; 103(6): 405-12. 377 Airee A, Draper HM, Finks SW. Aspirin resistance: disparities and clinical implications. 8. 378 Pharmacotherapy 2008; 28(8): 999-1018. 379 Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the 9. 380 prevention of atherothrombosis. N Engl J Med 2005; 353(22): 2373-83. 381 Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder 10. 382 status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250(1): 63-6. 383 Antithrombotic Trialists C, Baigent C, Blackwell L, et al. Aspirin in the primary and 11. 384 secondary prevention of vascular disease: collaborative meta-analysis of individual 385 participant data from randomised trials. Lancet 2009; 373(9678): 1849-60. 386 12. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 387 111(3): 733-44. 388 Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an 13. 389 in vitro platelet function analyzer--PFA-100. Semin Thromb Hemost 1995; 21 Suppl 2: 106-12. 390 14. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apher Sci 2003; 391 28(3): 307-17. 392 15. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J 393 *Thromb Haemost* 2003; **1**(8): 1710-3. 394 Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded 16. 395 determination of the natural history of aspirin resistance among stable patients with 396 cardiovascular disease. J Am Coll Cardiol 2003; 41(6): 961-5. 397 17. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in 398 patients with coronary artery disease. Am J Med 2007; 120(7): 631-5. 399 18. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A 400 comparison of six major platelet function tests to determine the prevalence of aspirin 401 resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28(14): 1702-8. 402 19. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM. High 403 on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 404 inhibition sensitive platelet function tests is associated with the occurrence of 405 atherothrombotic events. J Thromb Haemost 2010; 8(10): 2140-8. 406 Grove EL, Hvas AM, Johnsen HL, et al. A comparison of platelet function tests and 20. 407 thromboxane metabolites to evaluate aspirin response in healthy individuals and patients 408 with coronary artery disease. Thromb Haemost 2010; 103(6): 1245-53. 409 Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if 21. 410 any)? Eur Heart J 2007; 28(14): 1673-5. 411 22. Lev EI. Aspirin resistance transient laboratory finding or important clinical entity? J 412 Am Coll Cardiol 2009; 53(8): 678-80. 413 Muir AR, McMullin MF, Patterson C, McKeown PP. Assessment of aspirin resistance 23. 414 varies on a temporal basis in patients with ischaemic heart disease. *Heart* 2009; 95(15): 415 1225-9. 24. 416 Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-417 dose aspirin is not reflected consistently by platelet function assays: implications for aspirin 418 "resistance". J Am Coll Cardiol 2009; 53(8): 667-77.

419 25. Shen H, Herzog W, Drolet M, et al. Aspirin Resistance in healthy drug-naive men 420 versus women (from the Heredity and Phenotype Intervention Heart Study). Am J Cardiol 421 2009; **104**(4): 606-12. 422 26. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of 423 the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3(6): 1309-11. 424 Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical 27. 425 entity. Eur Heart J 2006; 27(6): 647-54. 426 Census and Statistics Department. Hong Kong Special Administrative Region. 28. 427 Thematic Household Survey Report No. 68. 2018. 428 https://www.censtatd.gov.hk/en/data/stat\_report/product/B1130201/att/B11302682019X 429 XXXB0100.pdf. 430 Wong AY, Root A, Douglas IJ, et al. Cardiovascular outcomes associated with use of 29. 431 clarithromycin: population based study. *bmj* 2016; **352**. 432 30. Shami JJP, Yan VKC, Wei Y, et al. Low-dose aspirin does not lower the risk of 433 colorectal cancer in patients with type 2 diabetes taking metformin. J Intern Med 2023; **293**(3): 371-83. 434 435 Zhou Y, Lin CJ, Yu Q, et al. Development and validation of risk prediction model for 31. 436 recurrent cardiovascular events among Chinese: the Personalized CARdiovascular DIsease 437 risk Assessment for Chinese model. European Heart Journal - Digital Health 2024. 438 Zhou Y, Lin CJX, Yu Q, et al. Primary Prevention Cardiovascular Disease Risk 32. Prediction Model for Contemporary Chinese (1° P-CARDIAC): Model Derivation and 439 440 Validation Using a Hybrid Statistical and Machine-Learning Approach. 441 van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained 33. 442 Equations in R. Journal of Statistical Software 2011; 45(3): 1 - 67. 443 34. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: 444 what is it and how does it work? Int J Methods Psychiatr Res 2011; 20(1): 40-9. 445 35. Tibshirani R. Regression Shrinkage and Selection Via the Lasso. Journal of the Royal 446 Statistical Society: Series B (Methodological) 1996; 58(1): 267-88. 447 36. Cox DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society: 448 Series B (Methodological) 1972; 34(2): 187-202. 449 37. Deo SV, Deo V, Sundaram V. Survival analysis—part 2: Cox proportional hazards 450 model. Indian journal of thoracic and cardiovascular surgery 2021; 37(2): 229-33. 451 Harrell FE. Regression modeling strategies: with applications to linear models, 38. 452 logistic regression, and survival analysis: Springer; 2001. 453 39. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. 454 Journal of the American Statistical Association 1958; 53: 457-81. 455 40. Davidson-Pilon C. lifelines: survival analysis in Python. Journal of Open Source 456 *Software* 2019; **4**(40): 1317. Transparent reporting of a multivariable prediction model for individual prognosis or 457 41. 458 diagnosis (TRIPOD): The TRIPODstatement. The UK EQUATOR Centre. 459 Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: 42. 460 Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343(8899): 687-91. 461 Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. *Nat Rev Cardiol* 43. 462 2011; **8**(10): 602-6. 463 44. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and

464 its clinical implications. *Ann Intern Med* 2005; **142**(5): 370-80.

465 45. Arruda-Olson AM, Reeder GS, Bell MR, Weston SA, Roger VL. Neutrophilia predicts 466 death and heart failure after myocardial infarction: a community-based study. Circ 467 Cardiovasc Qual Outcomes 2009; 2(6): 656-62. 468 46. Savonitto S, Granger CB, Ardissino D, et al. The prognostic value of creatine kinase 469 elevations extends across the whole spectrum of acute coronary syndromes. J Am Coll 470 Cardiol 2002; 39(1): 22-9. 471 47. Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a 472 high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite 473 clopidogrel pretreatment. Journal of the American College of Cardiology 2004; 43(6): 1122-6. 474 48. Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance. J Thromb 475 Thrombolysis 2002; 13(1): 49-56. 476 49. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin f2alpha 477 and platelet activation in diabetes mellitus: effects of improved metabolic control and 478 vitamin E supplementation. Circulation 1999; 99(2): 224-9. 479 50. Parker WAE, Sagar R, Kurdee Z, et al. A randomised controlled trial to assess the 480 antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. 481 Cardiovasc Diabetol 2021; 20(1): 238. 482 Selak V, Jackson R, Poppe K, et al. Predicting Bleeding Risk to Guide Aspirin Use for 51. 483 the Primary Prevention of Cardiovascular Disease: A Cohort Study. Ann Intern Med 2019; 484 **170**(6): 357-68. 485 52. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant 486 thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular 487 death in patients at high risk for cardiovascular events. *Circulation* 2002; **105**(14): 1650-5. 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 Table 1. Baseline characteristics of the derivation and validation cohorts

	Derivation cohort:		Validation cohort: Kowloon and New Territories			
	Hong Kong Island		Treatment group		Control group	
		(n=1,623)	(n=22,192)		(n=3,747)	
Demographic factors						
Age	67	(58-78)	68	(59-79)	75	(63-85)
Female sex	561	(35%)	8,404	(38%)	1,807	(48%)
Male sex	1,062	(65%)	13,788	(62%)	1,940	(52%)
Disease history						
Atrial fibrillation	74	(5%)	708	(3%)	390	(10%)
Dyslipidemia	215	(13%)	5,180	(23%)	431	(12%)
Diabetes	315	(19%)	4,404	(20%)	725	(19%)
Hypertension	492	(30%)	7,694	(35%)	1,488	(40%)
Chronic kidney disease	43	(3%)	563	(3%)	179	(5%)
Congestive heart failure	109	(7%)	1,379	(6%)	274	(7%)
Medication history						
Statins	288	(18%)	4,638	(21%)	784	(21%)
Antidiabetic drugs	242	(15%)	4,487	(20%)	841	(22%)
Antihypertensive	680	(42%)	12,556	(57%)	2453	(65%)
Count of medication	6	(4-8)	6	(5-9)	7	(5-10)
Clinical laboratory tests						
Neutrophil, 10^9/L	4.8	(3.6-6.7, 0%)	5.4	(4.0-7.7, 1%)	6.2	(4.3-9.8, 1%)
Creatine kinase, IU/L	140	(83-319, 14%)	136	(82-304, 10%)	112	(63-219, 11%)
Glucose (fasting), mmol/L	5.7	(5.2-6.9, 1%)	5.8	(5.2-7.0, 1%)	5.7	(5.1-7.0, 9%)

All data in n (%), median (interquartile range), or median (interquartile range, proportion of missing data).

Table 2. Summary of included 109 variables assessed in the model derivation cohort

Categories (number of	Risk variables		
variables)			
Demographic factors (2)	age, sex		
Family history of disease (2)	diabetes, <del>cardiovascular disease</del>		
Healthcare utilization (3)	outpatient visits per year*, accident and emergency visits per year, inpatien		
	visits per year		
Clinical laboratory tests (39)	neutrophil*^, creatine kinase (total)*^, monocyte*, glucose (fasting)^,		
	aspartate transaminase, alanine aminotransferase, low-density lipoprotein		
	cholesterol, hemoglobin A1c, prothrombin time, potassium (serum),		
	estimated glomerular filtration rate, triglycerides, basophil, albumin,		
	international normalized ratio, bilirubin (total), total cholesterol,		
	lymphocyte, creatinine (serum), platelet, red blood cell, high-density		
	lipoprotein cholesterol, body mass index, calcium (serum), white blood cell,		
	alkaline phosphatase, sodium (serum), eosinophil, hemoglobin, <del>thyroid</del>		
	stimulating hormone, diastolic blood pressure, systolic blood pressure,		
	erythrocyte sedimentation rate, C-reactive protein, bicarbonate (serum),		
	blood pH, free thyroxine, arterial partial pressure of oxygen, troponin I		
Medication history (24)	antidiabetic drugs*, count of medication*^, statins, antihypertensive drugs,		
	non-steroidal anti-inflammatory drugs, corticosteroids, proton-pump		
	inhibitors, H2-receptor antagonists, nicotine replacement therapy,		
	antiarrhythmic drugs, antithyroid drugs, psychotropic drugs, nitrates, thyroid		
	hormones, fibrates, other non-statin lipid-modifying drugs, <del>cardiac</del>		
	glycosides, omega-3 fatty acids, PCSK9 inhibitors, cholesterol absorption		
	inhibitors, bile acid sequestrants, testosterone, oestrogen, niacin		
Disease history (39)	dyslipidemia*^, pacemaker implantation, atrial fibrillation^, hypertension,		
	diabetes, congestive heart failure, thyroid disease, arrhythmia and		
	conduction disorders, obesity, oxygen therapy/ventilator/intubation,		
	asthma, injury and poisoning, severe mental illness, dementia, liver disease,		
	chronic obstructive pulmonary disease, cancer, renal disease, chronic kidney		
	disease, dialysis, Huntington's disease, erectile dysfunction, systemic lupus		
	erythematosus, Parkinson's disease, nephrotic syndrome, Creutzfeldt-Jakob		
	disease, Down's syndrome, defibrillator insertion, smoker, alcohol user,		
	heart transplantation, rheumatoid arthritis, hypothyroidism, cardioversion,		
	muscle pain or myopathy or rhabdomyolysis, migraine, cardiac		
	wall/valve/shunt replacement/repairment, cardiomyopathy, major organ		
	bleeding		

Strikethrough: excluded from LASSO regression due to high missing rate (>20%) or low event rate (<1%). \*Significant variables (p-value<0.05) in LASSO regression. ^Selected variables for final modeling. PCSK9 = Proprotein convertase subtilisin/kexin type 9.

Table 3. Multivariate stratification model for aspirin treatment effect

Variable	HR (95%CI)	p-value	points	
Atrial fibrillation	1.73 (1.33-2.24)	<0.05	1	
Dyslipidemia	1.19 (1.00-1.42)	0.06	1	
Hyperglycemia	1.19 (1.03-1.38)	<0.05	1	
Polypharmacy	1.23 (1.08-1.41)	<0.05	1	
Neutrophilia	1.45 (1.23-1.71)	<0.05	1	
Elevated CK	1.70 (1.46-1.99)	<0.05	1	

HR = hazard ratio. CI = confidence interval. Hyperglycemia = glucose > 7 (mmol/L).

Polypharmacy = concurrent medication > 4. Neutrophilia = neutrophil > 7.5 ( $10^9/L$ ). Elevated CK = creatine kinase > 400 (IU/L).

544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
5/5
5/0 577
5// 579
570 570
580
581

581 582

Table 4. Treatment effect stratification for low-dose aspirin compared to no aspirin treatment after the

	Number of	One-year aspirin	Number of patients	Proportion of patients
	VISTA risk factors	treatment effect (HR)		
	0	0.677 (0.569-0.806)	4,403	14.2%
	1-2	0.866 (0.810-0.927)	16,799	64.8%
-	3-6	0.991 (0.876-1.121)	5459	21.0%
83				
84				
85				
86				
87				
88				
89				
90 01				
91 0 <b>2</b>				
92				
94				
95				
96				
97				
98				
99				
00				
01				
02				
03				
04				
05				
06				
07				
08				
09				
10				
11				
12				
13				
14				
15				
10 17				
1 / 1 0				
1ð 10				
19 20				
∠∪ 21				
∠1 วว				
LL				



623		3,747	Control group: non-aspirin users
624	Figure 1. Selection of patients. Hong Kong West Cluster	is a part of Hong k	Kong Island. CVD = cardiovascular
625	diseases.		
626			
627			
628			
629			
630			
631			
632			
633			
634			
635			
636			
638			
630			
640			
641			
642			
643			
644			
645			
646			
647			
648			
649			
650			
651			
652			
653			
654 (55			
633 656			
657			
0.57			



658 659 660

**Figure 2. Outcomes by risk categories and treatment in the validation cohort.** Kaplan-Meier curves stratified by different risk categories and treatment groups (aspirin versus control). Number of patients in aspirin group

and control group in each risk category were shown after each subtitle (aspirin, control). One year Kaplan Meier CVD recurrence probability (1y KM) in the two groups, the corresponding absolute risk reduction (ARR),

663 and the hazard ratio (HR) with 95% confidence interval for aspirin versus control groups are shown.